This article is more than 5 years old. Information may no longer be current.
Regenxbio completes dosing in wet AMD phase 1/2a trial
Regenxbio has completed dosing in a phase 1/2a clinical trial of its wet age-related macular degeneration treatment candidate, RGX-314, according to a press release.
The trial enrolled 42 subjects who were previously treated with anti-VEGF injections in five escalating dose cohorts. They each received a single subretinal dose of RGX-314.
“Patients with wet AMD require intravitreal injections every 4 to 12 weeks, on average, with the current standard of care,” Steve Pakola, MD, Regenxbio chief medical officer, said in the release. “We were pleased to report durable treatment response from cohort 3 of the RGX-314 phase 1/2a trial for wet AMD at 1 year after a single administration of RGX-314 in a heavily pretreated patient population in our interim trial update earlier this month.”
Topline data from cohorts 4 and 5 are expected by the end of the year, with a phase 2b wet AMD trial and an investigational new drug application for RGX-314 in diabetic retinopathy planned for the second half of 2019, the release said.